RaySearch Laboratories AB (publ) (RSLBF)
RSLBF Stock Price Chart
Explore RaySearch Laboratories AB (publ) interactive price chart. Choose custom timeframes to analyze RSLBF price movements and trends.
RSLBF Company Profile
Discover essential business fundamentals and corporate details for RaySearch Laboratories AB (publ) (RSLBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Information Services
IPO Date
9 Jun 2015
Employees
416.00
Website
https://www.raysearchlabs.comCEO
Johan Lof
Description
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
RSLBF Financial Timeline
Browse a chronological timeline of RaySearch Laboratories AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 7 Nov 2025
Revenue estimate is $349.00M.
Earnings released on 8 Aug 2025
EPS came in at $0.09 falling short of the estimated $0.12 by -19.49%, while revenue for the quarter reached $31.86M , missing expectations by -90.42%.
Earnings released on 9 May 2025
EPS came in at $0.17 surpassing the estimated $0.11 by +45.69%, while revenue for the quarter reached $33.13M , missing expectations by -89.13%.
Earnings released on 21 Feb 2025
EPS came in at $0.16 surpassing the estimated $0.12 by +32.58%, while revenue for the quarter reached $29.04M , missing expectations by -1.33%.
Dividend declared on 21 Feb 2025
A dividend of $0.31 per share was announced, adjusted to $0.31. The dividend was paid on 30 May 2025.
Earnings released on 8 Nov 2024
EPS came in at $0.13 surpassing the estimated $0.06 by +100.31%, while revenue for the quarter reached $28.27M , beating expectations by +6.84%.
Earnings released on 16 Aug 2024
EPS came in at $0.17 surpassing the estimated $0.07 by +140.52%, while revenue for the quarter reached $30.17M , beating expectations by +18.99%.
Earnings released on 17 May 2024
EPS came in at $0.10 surpassing the estimated $0.07 by +39.05%, while revenue for the quarter reached $23.71M , missing expectations by -4.19%.
Earnings released on 23 Feb 2024
EPS came in at $0.09 surpassing the estimated $0.07 by +26.30%, while revenue for the quarter reached $29.64M , beating expectations by +1.79%.
Dividend declared on 23 Feb 2024
A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 29 May 2024.
Earnings released on 30 Sept 2023
EPS came in at $0.06 surpassing the estimated $0.01 by +291.09%, while revenue for the quarter reached $22.96M , beating expectations by +14.41%.
Earnings released on 30 Jun 2023
EPS came in at $0.03 surpassing the estimated $0.01 by +297.70%, while revenue for the quarter reached $22.07M , beating expectations by +13.32%.
Earnings released on 31 Mar 2023
EPS came in at $0.05 surpassing the estimated $0.04 by +31.60%, while revenue for the quarter reached $22.11M , beating expectations by +1.59%.
Earnings released on 28 Feb 2023
EPS came in at $0.41 surpassing the estimated $0.06 by +583.33%, while revenue for the quarter reached $25.82M , beating expectations by +16.52%.
Earnings released on 29 Nov 2022
EPS came in at $0.29 surpassing the estimated $0.05 by +480.00%, while revenue for the quarter reached $18.82M , beating expectations by +17.88%.
Earnings released on 29 Aug 2022
EPS came in at -$0.58 falling short of the estimated $0.31 by -287.10%, while revenue for the quarter reached $15.58M , missing expectations by -19.64%.
Earnings released on 18 May 2022
EPS came in at $0.56 falling short of the estimated $0.66 by -15.15%, while revenue for the quarter reached $22.18M , beating expectations by +0.43%.
Earnings released on 23 Feb 2022
EPS came in at -$0.47 falling short of the estimated -$0.20 by -135.00%, while revenue for the quarter reached $20.79M , beating expectations by +6.66%.
Earnings released on 18 Nov 2021
EPS came in at -$0.64 falling short of the estimated -$0.60 by -6.67%, while revenue for the quarter reached $15.54M .
Earnings released on 25 Aug 2021
EPS came in at -$0.48 falling short of the estimated -$0.13 by -269.23%, while revenue for the quarter reached $18.02M .
Earnings released on 5 May 2021
EPS came in at $0.21 falling short of the estimated $0.32 by -34.38%, while revenue for the quarter reached $18.54M .
Earnings released on 23 Feb 2021
EPS came in at -$0.41 falling short of the estimated $0.74 by -155.41%, while revenue for the quarter reached $19.40M .
Earnings released on 18 Nov 2020
EPS came in at -$0.76 falling short of the estimated -$0.13 by -484.62%, while revenue for the quarter reached $13.31M .
RSLBF Stock Performance
Access detailed RSLBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.